US2010305026A1PendingUtilityA1

CD44V6 peptides as inhibitors of bacterial infections

33
Assignee: KARLSRUHER INST FUR TECHNOLOGIEPriority: Feb 16, 2009Filed: Feb 16, 2010Published: Dec 2, 2010
Est. expiryFeb 16, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Christian JungVéronique Orian-RousseauAlexandra MatzkeHelmut Ponta
A61P 31/04C07K 14/70585A61K 38/12A61K 38/178Y02A50/30
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection.

Claims

exact text as granted — not AI-modified
1 . A method for the prevention and/or treatment of a bacterial infection in an individual comprising administering a peptide compound comprising the amino acid sequence set forth in amino acids 7 to 11 of SEQ ID NO: 2 or of SEQ ID NO: 1, or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method according to  claim 1 , wherein the peptide compound comprises SEQ ID NO: 2. 
     
     
         3 . The method according to  claim 2 , wherein the bacterial infection is an infection with an intracellular bacterium selected from the group consisting of  Listeria  spp.,  Mycobacterium  spp.,  Plasmodium  spp., and  Shigella  spp. 
     
     
         4 . The method according to  claim 3 , wherein the intracellular bacterium is  Listeria monocytogenes.    
     
     
         5 . The method according to  claim 2 , wherein the bacterial infection is listeriosis. 
     
     
         6 . The method according to  claim 2 , wherein the peptide compound is a cyclopeptide or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method according to  claim 1 , wherein the peptide compound comprises SEQ ID NO: 1. 
     
     
         8 . The method according to  claim 7 , wherein the bacterial infection is an infection with an intracellular bacterium selected from the group consisting of  Listeria  spp.,  Mycobacterium  spp.,  Plasmodium  spp., and  Shigella  spp. 
     
     
         9 . The method according to  claim 8 , wherein the intracellular bacterium is  Listeria monocytogenes.    
     
     
         10 . The method according to  claim 7 , wherein the bacterial infection is listeriosis. 
     
     
         11 . The method according to  claim 7 , wherein the peptide compound is a cyclopeptide or a pharmaceutically acceptable salt thereof. 
     
     
         12 . The method according to  claim 1 , wherein the bacterial infection is an infection with an intracellular bacterium. 
     
     
         13 . The method according to  claim 12 , wherein the intracellular bacterium is selected from the group consisting of  Listeria  spp.,  Mycobacterium  spp.,  Plasmodium  spp., and  Shigella  spp. 
     
     
         14 . The method according to  claim 13 , wherein the intracellular bacterium is  Listeria monocytogenes.    
     
     
         15 . The method according to  claim 1 , wherein the bacterial infection is listeriosis. 
     
     
         16 . The method according to  claim 1 , wherein the peptide compound is a cyclopeptide or a pharmaceutically acceptable salt thereof. 
     
     
         17 . A peptide compound comprising the amino acid sequence set forth in amino acids 7 to 11 of SEQ ID NO: 2 or of SEQ ID NO: 1, or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof. 
     
     
         18 . The peptide compound according to  claim 17 , wherein the peptide compound comprises SEQ ID NO: 2. 
     
     
         19 . The peptide compound according to  claim 17 , wherein the peptide compound comprises SEQ ID NO: 1. 
     
     
         20 . The peptide compound according to  claim 17 , wherein the peptide compound is a cyclopeptide or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.